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Abstract
Background: Concern over the potential cardiotoxicity of anti-malarial drugs inducing a prolonged
electrocardiographic QT interval has resulted in the almost complete withdrawal from the market of one anti-
malarial drug - halofantrine. The effects on the QT interval of four anti-malarial drugs were examined, using the
guinea pig heart.
Methods: The guinea pig heart was isolated, mounted on a Langendorff apparatus, and was then perfused with
pyruvate-added Klebs-Henseleit solutions containing graded concentrations of the four agents such as quinidine
(0.15 - 1.2 μM), quinine (0.3 - 2.4 μM), halofantrine (0.1 - 2.0 μM) and mefloquine (0.1 - 2.0 μM). The heart rate-
corrected QaTc intervals were measured to evaluate drug-induced QT prolongation effects.
Results: Quinidine, quinine, and halofantrine prolonged the QaTc interval in a dose-dependent manner, whereas
no such effect was found with mefloquine. The EC50 values for the QaTc prolongation effects, the concentration
that gives a half-maximum effect, were quinidine < quinine ≈ halofantrine.
Conclusions: In this study, an isolated, perfused guinea pig heart system was constructed to assess the cardiotoxic
potential of anti-malarial drugs. This isolated perfused guinea pig heart system could be used to test newly
developed anti-malarial drugs for their inherent QT lengthening potential. More information is required on the
potential variation in unbound drug concentrations in humans, and their role in cardiotoxicity.
Background
Worldwide, in 2006, an estimated 247 million (189-327
million) malaria cases occurred, with an approximated
881,000 (610,000-1,212,000) deaths [1]. Plasmodium
falciparum is the species that can cause severe, compli-
cated malaria and death. Intravenous (IV) quinine (a 4-
quinoline methanol) has been the mainstay of treatment
for such severe malaria, although in some countries,
including the United States, quinidine, the dextrorota-
tory diastereoisomer of quinine, is used because of the
non-availability of IV quinine. Parenteral forms of arte-
misinin derivatives are increasingly being used in devel-
oping countries and more recently also in industrialized
countries. Cardiac toxicity has been a major concern
with the use of IV quinine or quinidine, with quinidine
considered to be more toxic than quinine [2,3]. The pri-
mary mechanism of cardiotoxicity caused by quinine or
quinidine is the prolongation of the electrocardiographic
(ECG) QT interval which can cause potentially fatal
ventricular arrhythmias, including torsades de pointes,
and even sudden death.
Since the 1960s, chloroquine-resistant and multidrug-
resistant strains of P. falciparum have emerged in Africa
and Southeast Asia and have spread worldwide. Newer
anti-malarial drugs were developed including meflo-
quine, a 4-quinoline methanol similar to quinine, and
halofantrine, a 9-phenanthrene methanol structurally
related to quinoline anti-malarial drugs. Because both
drugs are administered orally, their widespread use was
anticipated for the treatment of uncomplicated cases of
drug-resistant P. falciparum infection. However, in
1993, reports of severe and sometimes fatal cardiotoxi-
city associated with the use of halofantrine led the
World Health Organization to limit its use [4], and as of
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2002, there were at least 20 reports of fatal cardiac com-
plications relating to use of the drug [5]. These events
were attributed to a QT prolongation effect of halofan-
trine, identified in several human studies of the drug
[6,7]. These unexpected cardiac problems resulted in the
withdrawal of the drug from the market in many coun-
tries except Pakistan and parts of West and Central
Africa [8], and underlines the importance of examining
the cardiotoxic potential of quinoline and other structu-
rally related anti-malarial drugs before the wider mar-
keting of newer drugs.
In this study, the effects on the QT interval of the fol-
lowing anti-malarials: quinidine, quinine, halofantrine,
and mefloquine were examined, using an isolated per-
fused guinea pig heart model. The aim of this study was
to clarify whether the results obtained from this model
could be used to predict the cardiotoxicity of these anti-
malarial drugs when used in clinical settings.
Methods
Chemical agents
Quinidine sulfate dihydrate and quinine hydrochloride
dihydrate were purchased from Wako Pure Chemical
Industries Ltd. (Tokyo, Japan). Mefloquine hydrochlor-
ide and halofantrine hydrochloride were kindly donated
by Roche Co. Ltd. (Basel, Switzerland) and SmithKlein
Beecham Co. Ltd. (Brentford, UK), respectively. All
other chemicals used were of the reagent grade and
were purchased commercially.
Isolation of guinea pig hearts
The isolated perfused guinea pig heart system used in
this study was constructed using a method described
elsewhere [9]. Male Hartley guinea pigs weighing 350 to
500 g were anesthetized with a mixture of urethane and
a-chloralose (1.2 and 30 mg/kg, respectively, intraperito-
neally), and then injected with heparin (500 U/body,
intraperitoneally). After 30 min, the heart was promptly
excised. After the aorta was cannulated, the heart was
mounted on a Langendorff apparatus and perfused with
the pyruvate-added Klebs-Henseleit solution composed
of: NaCl, 118 mM; KCl, 4.7 mM; CaCl2, 2.55 mM;
MgSO4, 1.18 mM; KH2PO4, 1.18 mM; NaHCO3, 24.88
mM; glucose, 11.1 mM; sodium pyruvate, 2 mM; ascor-
bic acid, 0.14 mM; EDTA2Na, 0.5 mM. The solution
was aerated with O2: CO2 (95:5) and kept at 37°C (pH
7.4 ± 0.01). The perfusion pressure was kept at 85 cm
of water. The sinoatrial node of the heart was crushed
after perfusion was commenced.
Electrocardiogram recording
An ECG recording of the epicardial surface was com-
menced immediately after attaching the heart to the
Langendorff apparatus. A stimulator was seated at the
right atrium and the heartbeats were artificially kept
constant at 210 per min by 3.5 Hz stimuli. Two silver
wire electrodes were placed on the epicardial surface.
Signals from both electrodes were amplified by an elec-
tric amplifier (AB-621G, Nihon-Kohden, Tokyo),
recorded on a personal computer (PC-9801VX, NEC,
Tokyo) via an A/D converter (Analog-Pro Jr., Canopus
Electric, Kobe), and analysed with WAVE MASTER II
and WM Read (Canopus Electric, Kobe) as described
previously [10,11].
QT interval measurement
Quinidine, quinine, and mefloquine were dissolved in
Klebs-Henseleit solution at 0.15 - 1.2 μM, 0.3 - 2.4 μM,
0.1 - 2.0 μM, respectively. Halofantrine, which is poorly
water-soluble, was first dissolved in polyethylene glycol
400 (PEG) and then in Klebs-Henseleit solution at 0.1 -
2.0 μM, with a final PEG concentration of 0.1% (v/v).
The anti-malarial drug free 0.1% PEG Klebs-Henseleit
solution served as a control for halofantrine treatment.
Each heart was allowed to equilibrate with the drug-free
solutions for 30 min. Measurements were performed
after perfusion with the drug-containing solutions for 15
min. ECG parameters such as the heart rate, QT or
QaT (from the beginning of the Q wave to the top of
the T wave) intervals were obtained from the average
wave shape of recordings for 10 sec.
Analysis of the QT interval prolongation
QTc and QaTc intervals were obtained after correction
of QT and QaT intervals using the Bazett’s formula
[12], since the formula was shown to be applicable to
the guinea pig heart [13]. The QT prolongation effects
of each drug were fitted simultaneously according to the
full nonlinear regression analysis for effect as expressed














Where E is the change in QaTc interval, Emax is the
maximum effect of the drug, Emin is the minimum effect
of the drug, EC50 is the concentration that gives a half-
maximum effect, and C is the concentration of drug.
Each parameter was calculated by the simultaneous fit-
ting using a nonlinear least-squares programme
(MULTI) with the modified Marquardt method [14].
Statistics
Change in the QaTc interval is expressed as a mean ±
standard error of the mean (SEM) and EC50 is expressed
as a mean ± standard deviation (SD). Statistical analysis
was performed using the Student’s t-test.
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Results
Perfusion with quinidine
Perfusion of the isolated guinea pig heart with the control
solutions showed no QTc prolongation effect. To assess
the optimal experimental conditions, the hearts were per-
fused with graded concentrations of quinidine (the proto-
type anti-malarial drug carrying cardiotoxic potential).
Quinidine prolonged both the QTc and QaTc intervals at
concentrations of 0.15 - 1.2 μM in a dose dependent man-
ner. The EC50 for the QTc and the QaTc interval was 0.45
and 0.49 μM, respectively. Unexpectedly, the QTc interval
proved difficult to measure at high drug concentrations as
the end of the T-wave was unclear, overlapping the follow-
ing P-wave. Therefore, it was decided to use the QaTc
instead of the QTc interval to assess drug-induced QT
lengthening throughout this study.
Effects of anti-malarial drugs on the QaTc interval
Figure 1 shows the relationship between concentrations
of the four anti-malarial drugs and the changes in
the QaTc interval. Quinidine and quinine prolonged the
QaTc interval in a dose dependent manner within the
range of concentrations described above. Statistically,
the QaTc prolongation effect was significantly higher
with quinidine than quinine at concentrations of 0.3 and
1.2 μM (p <0.05). Halofantrine also prolonged the QaTc
interval in a dose dependent manner within the range of
concentrations described above. The EC50 values of qui-
nidine, quinine, and halofantrine were 0.49 ± 0.61, 1.68
± 0.43, 1.59 ± 1.26 μM, respectively, and thus the in
vitro QaTc prolongation effect was highest with quini-
dine, and those with quinine and halofantrine were simi-
lar and were lower than that with quinidine. In contrast,
mefloquine did not prolong the QaTc interval within
the range of concentrations of 0.5 - 2.0 μM.
Discussion
An isolated, perfused guinea pig heart system was
constructed to assess the cardiotoxic potential of anti-
malarial drugs. While the cardiotoxic effects of halofan-
trine have been studied previously using a similar (feline
heart) model [15], there have been no previous studies
reported where the cardiotoxic potential of several anti-
malarial drugs were assessed simultaneously.
Quinidine, quinine, and halofantrine, all of which have
been known to have potential cardiotoxicity in humans,
Figure 1 Relationships between QaTc changes and concentrations of quinidine (A), quinine (B), halofantrine (C), and mefloquine (D) in
the isolated perfused guinea pig heart system. Each bar represents the mean ± SEM (n = 3 - 4). *Statistically significant compared with the
same concentrations of quinine (p < 0.05).
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exerted a QT prolongation effect in this experimental
model. The effects of the three anti-malarial drugs were
shown to be dose-dependent at the drug concentrations
tested. In general, the biologically active component is
considered to be the unbound drug, and the therapeutic
range of unbound quinine in African children was
shown to be 0.2 - 2.0 mg/mL (0.62 - 6.2 μM) [16]. This
suggests that the quinine concentrations used in this
experimental model may prove clinically relevant. The
observed higher QT prolongation effect of quinidine
(EC50 = 0.49 ± 0.61 μM) over quinine (1.68 ± 0.43 μM) is
consistent with the findings in humans that the former is
more cardiotoxic than the latter in terms of developing
serious ventricular arrhythmias [2] and prolonging the
QT interval [3]. An in vitro study was conducted on the
inhibition of potassium channel currents on Xenopus
oocytes expressing the human ether-a-go-go-related gene
(hERG), which represents an underlying molecular
mechanism of QT prolongation [17]. This study also
showed that quinidine was more toxic than quinine with
IC50 values of 4.6 μM and 57 μM, respectively. In addi-
tion to this inherent difference in cardiotoxic potential
between quinidine and quinine, the former was reported
to have a higher unbound fraction than the latter [18].
When assessing cardiotoxicity in human therapies, the
possibility of finding differences in unbound fractions of
an anti-malarial drug should also be considered. For
example, the plasma unbound fraction of quinine was
reported to be lower in cerebral malaria than in uncom-
plicated malaria [19], which may explain why severe qui-
nine toxicity is unusual in severe falciparum malaria [20].
Moreover, studies are needed to investigate the various
factors that could influence the total concentration and
consequently the unbound concentration of an anti-
malarial drug to ensure safer use of drugs.
Mefloquine did not prolong the QT interval within
the range of concentrations of 0.5 - 2.0 μM. This agent
is characterized by its very high protein binding, e.g,
98.3% shown in humans [21], with the unbound plasma
mefloquine concentration in human therapy reported to
be 0.05 μM [22]. This concentration is below the lowest
concentration used in this study, making it very unlikely
to be cardiotoxic in clinical settings. In fact, although
Davis et al [23] suggested a mild and transient QTc
lengthening in humans after mefloquine use, this was
not evident in other studies [6,24], consistent with the
expert’s view that there is no convincing evidence for
significant cardiotoxicity following mefloquine adminis-
tration [2]. The possible mefloquine-induced cardiotoxi-
city might, however, be due to another mechanism, i.e.,
reduced contractility of cardiac muscles due to inhibi-
tion of the L type Ca2+ channel by mefloquine [25].
The findings of this study, which showed that the QT
prolongation effect of halofantrine was lower than that
of quinidine and similar to that of quinine, may not
seem to be clinically relevant. There are, however, few
studies in which the therapeutic levels of unbound halo-
fantrine concentrations in humans are well defined. One
study showed the average peak total halofantrine con-
centration to be 6.4 μM [26], and the serum protein
binding rate of halofantrine was reported to be 83%
[27]. Therefore, the average peak unbound halofantrine
concentration was calculated as 1.2 μM.
Other reports showed that the unbound therapeutic
plasma concentration was 0.57 μM [22]. According to
the results of this study, these reportedly low concentra-
tions in humans do not seem to lengthen the QT inter-
val. However, halofantrine is characterized by its marked
differences in plasma concentrations among individuals,
with one individual showing a five-times higher peak
concentration than the other [26]. It has also been
reported that its absorption is significantly enhanced
when administered with fatty food (6.6 times higher
peak concentrations) [28] or grapefruit juice [29]. In
addition, the metabolite desbutylhalofantrine was shown
to have some QT interval prolongation effect in a rabbit
model [30]. Alternatively, the inherent cardiotoxicity of
halofantrine may be detected more sensitively in other
experimental models. For example, another in vitro
study of inhibition of the potassium channel currents
on hERG transfected cells, the IC50 was as low as
0.04 μM for halofantrine whereas it was 2.6 μM for
mefloquine [22].
To assess cardiotoxicity of an anti-malarial drug, fac-
tors other than the inherent QT prolongation potential
as shown in this study and the plasma unbound drug
concentration need to be considered. For instance, accu-
mulation in the myocardium may differ between anti-
malarial drugs [22]. Furthermore, one report showed an
absence of QT prolongation with an increased fraction
of unbound quinidine induced by heparin administra-
tion [31]. Therefore, caution must be exercised when
simply applying findings of unbound drug levels to
assess cardiotoxicity in clinical settings.
Conclusion
The results of this study were largely consistent with the
reported cardiotoxicity of the four anti-malarial drugs in
clinical use. This isolated perfused guinea pig heart sys-
tem could be used to test newly developed anti-malarial
drugs for their inherent QT lengthening potential. More
knowledge is required on the variability of unbound
anti-malarial drug concentrations in humans, as well as
their impact on cardiotoxicity in clinical settings.
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